Delivery Order SPE2DB24D1021-SPE2DB25FEWCS
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $1,658.76 to AmerisourceBergen Drug Corp for the supply of Vyvanse capsules (30 mg) on August 20, 2025. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation, leveraging...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 20 mg capsules (100-count units) on August 25, 2025, with a ceiling value of $1,781.07 and an ultimate completion date of August 26, 2025. This contract was awarded competitively with no set-aside designation and utilizes firm fixed-price pricing. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a contract value of $1,552.17. This competitively awarded, non-set-aside delivery order is structured as a firm fixed price contract with an ultimate completion date of July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Vyvanse 60 mg capsules (100-count units) at a ceiling value of $1,178.44. This competitively awarded, firm fixed-price delivery order is scheduled for completion by April 25, 2025, with performance originating from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation and represents a child contract under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Vyvanse 50 mg capsules in quantities of 100 units. This competitively awarded, firm fixed-price contract carries a ceiling value of $8,465.58 and is scheduled for completion by September 5, 2025. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Vyvanse 40 mg capsules (100 count) with a ceiling value of $1,253.12. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 2, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a contract value of $1,066.12 and an ultimate completion date of July 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award is issued under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,174.23 to AmerisourceBergen Drug Corp for the supply of Vyvanse 30 mg capsules (100 count) on June 2, 2025, with an ultimate completion date of June 3, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) at a ceiling value of $2,079.25. This is a firm fixed-price delivery order with an ultimate completion date of July 28, 2025. The award represents a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 10, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) with a ceiling value of $2,584.08. This firm fixed-price delivery order, which is due for completion by June 11, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026. The award was...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FEWCSDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 50 mg capsules (quantity 100s) on April 22, 2025, with a ceiling value of $1,642.71 and an ultimate completion date of April 23, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, is a critical federal medical supplier supporting military and veteran healthcare systems through its comprehensive product portfolio spanning brand-name and generic medications across multiple therapeutic domains. AmerisourceBergen's federal contracting demonstrates consistent capability in meeting competitive procurement requirements for pharmaceutical delivery to defense medical supply chains. The company's role as a pharmaceutical prime vendor enables it to supply diverse medical commodities—including specialty medications, vaccines, and medical devices—to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This particular delivery order for Vyvanse, a controlled-release amphetamine used in attention deficit hyperactivity disorder treatment, reflects the company's ongoing support for military medical procurement needs. No set-aside provisions were applied to this award.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 4/22/25 |